Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Reference: FOLFOXIRI with Panitumumab for 1st Line Metastatic RAS/RAF WT Colorectal Cancer
The phase III TRIPLETE study shows that upfront mFOLFOXIRI plus panitumumab improved overall survival in patients with metastatic colorectal cancer compared to mFOLFOX plus panitum
New Reference: Erdafitinib for Cisplatin-Ineligible FGFR-Altered Metastatic Urothelial Carcinoma
Erdafitinib alone and in combination with cetrelimab demonstrated significant antitumor activity among cisplatin-ineligible patients with metastatic FGFR-altered urothelial carcino
New Reference: Datopotamab for HR-Positive HER2-Negative Metastatic Breast Cancer
Datopotamab deruxtecan showed a significant improvement in progression-free survival compared to investigator's choice chemotherapy. Overall survival did not show statistical signi
New Reference: Carboplatin with EC->T for Early-Stage Triple-Negative Breast Cancer
In this phase III trial, adding carboplatin to standard epirubicin, cyclophosphamide, and taxane regimen improved disease-free, distant disease-free, and overall survival in patien
New Protocol: Cabozantinib + Temozolomide for Leiomyosarcoma
Cabozantinib and temozolomide combination demonstrated promising clinical benefit in patients with unresectable or metastatic leiomyosarcoma. The treatment showed manageable advers
New Drug: SubQ Amivantamab with Lazertinib for EGFR-Mutated NSCLC
In the PALOMA-3 study, subcutaneous amivantamab-lazertinib showed noninferior efficacy to intravenous administration with improved safety and convenience. The subcutaneous route si
New Reference: Niraparib – Abiraterone for HRR-Deficient Metastatic Castration-Sensitive Prostate Cancer
The addition of niraparib to abiraterone significantly improved progression-free survival in patients with HRR-deficient metastatic prostate cancer. Safety analysis showed higher r
New Protocol: Epcoritamab with Rituximab and Lenalidomide for Follicular Lymphoma
The EPCORE FL-1 trial demonstrated that epcoritamab combined with lenalidomide and rituximab significantly improved response rate and progression-free survival compared to lenalido
New Reference: Vorasidenib for IDH1/IDH2-Mutant Low-Grade Gliomas
In the phase 3 INDIGO trial, vorasidenib significantly improved progression-free survival and time to next intervention over placebo for IDH1/2-mutant glioma. The treatment reduced
